DARUNAVIR 600 600MG TABLET

Dosage

Children: Paediatric dosing for amorphous drugs should be determined based on the specific drug and its formulation. Refer to the relevant pediatric dosing guidelines for accurate dosing.

Adults: Dosage for amorphous drugs will depend on the specific medication and its formulation. Refer to the specific drug information for appropriate dosing.

Mechanism of action

The mechanism of action for amorphous drugs typically involves enhanced solubility leading to increased bioavailability. This is particularly important for drugs that have low water solubility. The amorphous state allows for a greater proportion of the drug to be in solution at a given time, facilitating absorption through biological membranes.

Pharmacodynamics

Pharmacodynamics of amorphous drugs can vary widely based on the specific drug in question. Generally, the increased solubility and dissolution rate in the amorphous form can lead to a quicker onset of action and potentially higher peak plasma concentrations, resulting in more pronounced effects. The relationship between drug concentration and effect can be more pronounced with amorphous formulations.

Pharmacokinetics

The pharmacokinetics of amorphous drugs often show improved absorption characteristics. Due to their amorphous nature, these drugs may reach peak plasma concentrations faster and have altered distribution and elimination profiles compared to their crystalline forms. However, specific pharmacokinetic parameters will depend on the individual drug and its formulation.

Pregnancy

Safety in pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Unknown if excreted in human milk. Use caution when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• HIV-1 infection
• HIV-1 infection in treatment-experienced patients
• HIV-1 infection in treatment-naive patients

Dosage

Children: Refer to BNF for Children for appropriate dosing in pediatric patients.

Adults: Refer to specific guidelines or BNF for exact dosing information, as it may vary based on patient factors.

Mechanism of action

Darunavir inhibits the HIV-1 protease enzyme, which is essential for the viral maturation process. By binding to the active site of the protease, darunavir prevents the cleavage of viral polyproteins into functional proteins, thereby inhibiting the production of infectious viral particles.

Pharmacodynamics

Darunavir exhibits potent antiviral activity against HIV-1 and is effective in reducing viral load. Its high barrier to resistance is attributed to its structural design, which allows it to maintain efficacy against many protease inhibitor-resistant viral strains. The drug's antiviral effects are characterized by a rapid decline in plasma HIV RNA levels, typically observed within the first weeks of therapy.

Pharmacokinetics

Darunavir is well-absorbed after oral administration, with peak plasma concentrations occurring approximately 2 to 4 hours post-dose. It is highly protein-bound (about 92-95%) and has a long half-life, allowing for once-daily dosing in many cases. The metabolism of darunavir occurs primarily via the liver enzyme CYP3A4, and it is excreted in the feces. Its pharmacokinetics can be affected by co-administered drugs that induce or inhibit CYP3A4.

Contra-indications

• Severe hypersensitivity to darunavir or any component of the formulation.
• Concomitant use with certain medications that may lead to significant drug interactions.

Adverse effects

• Nausea
• Diarrhea
• Rash
• Fatigue
• Headache
• Elevated liver enzymes
• Hyperlipidemia

Interactions

• May interact with other antiretroviral agents, especially those that are substrates, inhibitors, or inducers of CYP3A4.
• Significant interactions with certain anticonvulsants, antimycobacterial agents, and other drugs metabolized by cytochrome P450 enzymes.

Precautions

• Monitor liver function tests regularly, especially in patients with a history of liver disease.
• Caution in patients with hemophilia as there may be an increased risk of bleeding.
• Assess for potential drug interactions before initiating therapy.

Pregnancy

Darunavir is classified as Category C. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not recommended to breastfeed while taking darunavir due to the potential risk of transmission to the infant.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Darunavir 75 mg, 150 mg, 300 mg film-coated tablets
• Darunavir 100 mg/mL oral suspension